Eisai deal a vote of confidence in Arena's obesity drug
This article was originally published in Scrip
Executive Summary
Eisai has acquired exclusive rights to commercialise Arena Pharmaceuticals' novel obesity and weight management drug lorcaserin in the US, in an alliance which could eventually be worth well over $1 billion to the US firm.